Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $25M | $-154M | $-144M | $-130M | -47.0% | -87.9% | -319.0% |
| 2024 | $211M | $51M | $66M | $-45M | 15.3% | 63.4% | -1081.7% |
| 2023 | $129M | $-0M | $-7M | $134M | -2.8% | - | -92.9% |
| 2022 | $0M | $-95M | $-95M | $-97M | -44.5% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 25.42 |
| Operating Revenue | 25.42 |
| Operating Expense | 183.32 |
| Research And Development | 142.27 |
| Selling General And Administration | 41.05 |
| Total Expenses | 183.32 |
| Operating Income | -157.90 |
| Total Operating Income As Reported | -157.90 |
| EBITDA | -153.80 |
| Normalized EBITDA | -153.80 |
| EBIT | -157.90 |
| Interest Income | 15.07 |
| Net Interest Income | 15.07 |
| Interest Income Non Operating | 15.07 |
| Net Non Operating Interest Income Expense | 15.07 |
| Pretax Income | -142.83 |
| Tax Provision | 0.92 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -143.75 |
| Net Income From Continuing And Discontinued Operation | -143.75 |
| Net Income From Continuing Operation Net Minority Interest | -143.75 |
| Net Income | -143.75 |
| Net Income Common Stockholders | -143.75 |
| Net Income Including Noncontrolling Interests | -143.75 |
| Normalized Income | -143.75 |
| Diluted NI Availto Com Stockholders | -143.75 |
| Basic Average Shares | 41.37 |
| Diluted Average Shares | 41.37 |
| Reconciled Depreciation | 4.10 |
| General And Administrative Expense | 41.05 |
| Other Gand A | 41.05 |
| Total Other Finance Cost | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Entrada Therapeutics, Inc.this co. | TRDA | $272M | -1.89 | 0.89 | -47.0% | -1.51 |
| OraSure Technologies, Inc. | OSUR | $287M | -4.18 | 0.84 | -20.2% | -1.74 |
| Niagen Bioscience, Inc. | NAGE | $279M | 16.04 | 3.64 | 22.7% | 13.78 |
| Quantum-Si incorporated | QSI | $279M | -2.75 | 1.27 | -46.0% | -2.81 |
| Eledon Pharmaceuticals, Inc. | ELDN |
| - |
| - |
| - |
| - |
| - |
| - |
| $278M |
| -6.09 |
| 3.43 |
| -56.3% |
| -3.08 |
| Anavex Life Sciences Corp. | AVXL | $261M | -5.63 | 2.75 | -48.9% | - |
| Akebia Therapeutics, Inc. | AKBA | $260M | -48.70 | 7.98 | -16.4% | 5.86 |
| Fate Therapeutics, Inc. | FATE | $258M | -1.89 | 1.24 | -65.8% | -2.14 |
| Nuvectis Pharma, Inc. | NVCT | $257M | -9.70 | 13.93 | -143.6% | - |
| Peer Median | - | -4.91 | 3.09 | -47.5% | -1.94 | |